Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardiometabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Jasmine Fels - UBS Luca Issi - RBC Capital Andrea Newkirk - Goldman Sachs Maury Raycroft - Jefferies Dina Ramada ...

EXHIBIT 99.1 PRESS RELEASE November 26, 2024 Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results Conference Call and Webcast Today, November 26, 2024 at 4:30 p.m. ET PASADENA, Calif., November 26, 2024 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. "Arrowhead is well positioned, both individually and with ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-K __________________________________________________________________ (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38042 _________ ...

Key TakeawaysArrowhead Pharmaceuticals reported a Phase-3 study of its medicine for a rare genetic disorder met all its primary endpoints and key secondary endpoints.The drug, called Plozasiran, helped patients with familial chylomicronemia syndrome (FCS), which has no currently approved treatment.Arrowhead said it plans to file a new drug application with the Food and Drug Administration (FDA) this year. Shares of Arrowhead Pharmaceuticals (ARWR) gained Tuesday after the biotech firm announced positive res ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference August 14, 2024 2:00 PM ET Company Participants Vincent Anzalone - Vice President and Head of Investor Relations Dr. Carel Le Roux - Chair of Metabolic Medicine, University College Dublin Erik Bush - Senior Vice President, Biology Tao Pei - Senior Vice President, Discovery Chemistry James Hamilton - SVP, Discovery and Translational Medicine Operator Good afternoon, and welcome to the Arrowh ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference August 14, 2024 2:00 PM ET Company Participants Vincent Anzalone - Vice President and Head of Investor Relations Dr. Carel Le Roux - Chair of Metabolic Medicine, University College Dublin Erik Bush - Senior Vice President, Biology Tao Pei - Senior Vice President, Discovery Chemistry James Hamilton - SVP, Discovery and Translational Medicine Operator Good afternoon, and welcome to the Arrowh ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President and CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - Senior Vice President and Head of Global Cardiometabolic Franchise Ken Myszkowski - CFO James Hamilton - Chief Discovery and Translational Medicine Patrick O'Brien - COO and General Counsel Conference Call Participants Maury Raycroft - Jefferies Ellie Merle - UBS Luca ...

EXHIBIT 99.1 PRESS RELEASE August 8, 2024 Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results – Conference Call and Webcast Today, August 8, 2024 at 4:30 p.m. ET PASADENA, Calif., August 8, 2024 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 third quarter ended June 30, 2024. The Company is hosting a conference call today, August 8, 2024, at 4:30 p.m. ET to discuss the results. "Arrowhead had a very productive quarter with several high- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38042 _____________________________________ ARROWHEAD PHAR ...

If you’re wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price. Yet, the reality is that the average annual S&P 500 return is approximately 10%. At that rate the law of 72 states that an investor can expect their capital to double roughly every 7 years. Thus, those seeking 100% returns by 2025 will have to take some risks. There is effectively zero chance that an average strategy will double an investor’s returns within that time frame. That doe ...